Life Sciences Tools and Services
Company Overview of Retina Implant AG
Retina Implant AG researches, develops, and produces medical products for visually handicapped and blind patients. It primarily focuses on the development of subretinal implants. The company was founded in 2003 and is based in Reutlingen, Germany.
Founded in 2003
Key Executives for Retina Implant AG
Compensation as of Fiscal Year 2014.
Retina Implant AG Key Developments
Retina Implant AG Announces Multicenter Clinical Trial Results at Spain's Ophthalmology Congress
Mar 10 14
Retina Implant AG announced that Angelika Braun, clinical engineer at Retina Implant AG, presented results from the Company's multicenter clinical trial for the first time in Spain at the XVII Congreso de Sociedad Espanola de Retina y Vitreo (SERV) 2014. SERV 2014 took place 7-8 March at the Palacio de Exposiciones y Congresos de Sevilla in Sevilla, Spain. As part of the trial, study participants were implanted with Retina Implant's Alpha IMS device, a small, wireless microchip that is implanted below the retina, specifically in the macular region. The microchip mimics the function of the photoreceptors within the eye and has shown to restore partial vision to those blinded for years, allowing them to perceive light, detect motion, read letters and perform daily tasks with improved acuity and mobility in everyday life. Braun's presentation, 'Ver con un implante electronico subretinal en la vida diaria', featured results from a subset of nine patients in the trial. Functional vision was restored in the majority of these patients, enabling improved function in everyday life. Examples include the ability to recognize faces, distinguish objects such as telephones and read signs on doors.
Retina Implant AG Announces the Publication of Study Results on Alpha IMS Implant in Proceedings of the Royal Society B
Feb 20 13
Retina Implant AG announced results from part of its multicentre study were published in the peer-reviewed journal Proceedings of the Royal Society B. The research found that, during the course of a three to nine month observation period, functional vision was restored in the majority of nine German patients implanted with a subretinal microchip as part of the first module of the Company's second human clinical trial. In addition, visual acuity for two of the nine patients surpassed the visual resolution of patients from the Company's first human clinical trial.
Retina Implant AG Presents Clinical Trial Update Scientific Advisory Board
Sep 27 12
Retina Implant AG announced that its scientific advisory board has been debriefed on the latest results in the company's second human clinical trial. On September 23 Lead Investigator Eberhart Zrenner, M.D., professor of Ophthalmology and founding director of the Institute for Ophthalmic Research at the Centre for Ophthalmology of the University of Tubingen, presented to the advisory board results from Retina Implant's multi-center, human clinical trial with wireless subretinal implant Alpha IMS which is currently underway in Germany, the UK and China and has involved 18 patients to date. In human clinical trials since 2005, Retina Implant's subretinal implant technology consists of a 3x3 mm(2) microchip with 1,500 electrodes that is implanted below the retina in the macular region. Results from the Company's first human clinical trial were published in Proceedings of the Royal Society B in November 2010 and showed that patients involved in the study were able to recognize foreign objects and to recognize letters to form words with the company's "bionic eye." The second human clinical trial, using Retina Implant's new, wireless device in patients' home environments as well as in the laboratory setting, began in Germany in May 2010 and has since expanded into two additional sites in Germany, two sites in the UK as well as one site in China.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|